Sarosiek, Kristopher A <br/><br/>
Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.  [electronic resource] 

 -  British journal of haematology  Nov 2009 
 - 308-18 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2141.2009.07851.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibiotics, Antineoplastic--pharmacology<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Apoptosis Regulatory Proteins--biosynthesis<br/>Doxorubicin--pharmacology<br/>Drug Evaluation, Preclinical--methods<br/>Germinal Center--pathology<br/>Humans<br/>Interleukin-4--pharmacology<br/>Lymphocyte Activation<br/>Lymphoma, Large B-Cell, Diffuse--metabolism<br/>Neoplasm Proteins--biosynthesis<br/>Phosphatidylinositol 3-Kinases--physiology<br/>Recombinant Proteins--pharmacology<br/>Rituximab<br/>Tumor Cells, Cultured